Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharmaceuticals Industries Buyback Yield % Chart
BOM:524715 vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharmaceuticals Industries's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharmaceuticals Industries Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharmaceuticals Industries's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Sun Pharmaceuticals Industries's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharmaceuticals Industries (BOM:524715) has a Buyback Yield % of 0.00 as of Aug. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sun Pharmaceuticals Industries and its competitors. Over the past decade, Sun Pharmaceuticals Industries' Buyback Yield % has ranged from 0.02 to 1.65. According to the industry distribution chart, Sun Pharmaceuticals Industries ranks #999999 out of 248 companies in the Drug Manufacturers industry.
Is Sun Pharmaceuticals Industries' Buyback Yield % too high?
Sun Pharmaceuticals Industries' current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.65. Based on the distribution chart, Sun Pharmaceuticals Industries ranks #999999 out of 248 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sun Pharmaceuticals Industries has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharmaceuticals Industries' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharmaceuticals Industries ranks #999999 out of 248 companies for Buyback Yield %. This places Sun Pharmaceuticals Industries in the lower half of its industry. Historically, Sun Pharmaceuticals Industries' own Buyback Yield % has ranged from 0.02 to 1.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sun Pharmaceuticals Industries and its competitors. Sun Pharmaceuticals Industries's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharmaceuticals Industries stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries (BOM:524715) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,954.87, compared to a current price of ₹1,900.90 — trading 2.8% below its estimated fair value. The current Buyback Yield % is 0.00. Sun Pharmaceuticals Industries' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sun Pharmaceuticals Industries (BOM:524715), the current Buyback Yield % is 0.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharmaceuticals Industries (BOM:524715) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries stock appears to be undervalued.
The current stock price of ₹1,900.90 is trading 2.8% below its estimated GF Value™ of ₹1,954.87.
GuruFocus considers Sun Pharmaceuticals Industries to be Fairly Valued.
Key valuation signals for BOM:524715:
Buyback Yield %: 0.00
GF Value™: ₹1,954.87 vs. price of ₹1,900.90 (2.8% below fair value)
No single metric tells the full story. See the BOM:524715 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
92GF Score
Get the complete analysis for BOM:524715
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524715 has been successfully added to your 
